Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
Primary Purpose
Non-small Cell Lung Cancer
Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Rociletinib
Trametinib
Sponsored by

About this trial
This is an interventional treatment trial for Non-small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- Written informed consent on an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF before any study-specific evaluation
- Histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with EGFR activating mutation (excluding exon 20 insertion); measurable disease per RECIST 1.1
- Prior treatment with an EGFR TKI; in Phase 2, prior treatment with a T790M-directed EGFR TKI for patients in Group B. Previous chemotherapy is allowed; in Phase 2, immediate prior therapy must be EGFR TKI
- Patient willingness to undergo tumor biopsy at baseline and on treatment (optional for Phase 1; mandatory for Phase 2)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1; life expectancy at least 3 months
- Adequate hematological and biological function; LVEF ≥50%
Exclusion Criteria:
- Documented evidence in tumor of exon 20 insertion, small cell transformation, or MET amplification
- Leptomeningeal carcinomatosis or other untreated or symptomatic CNS metastases (asymptomatic CNS metastases allowed if clinically stable without requirement for steroids within 2 weeks)
- Known preexisting interstitial lung disease or pneumonitis
- Concurrent use of QT-prolonging medication
- Uncontrolled diabetes (HA1C > 10%) despite optional therapy
Cardiac abnormalities:
- Clinically significant abnormal 12-lead ECG, QT interval corrected using Fridericia's method (QTcF) >450 ms
- Inability to measure QT interval on ECG
- Personal or family history of long QT syndrome
- Implantable pacemaker or implantable cardioverter defibrillator
- Resting bradycardia < 55 beats/min
- Inability to swallow oral study treatment or any gastrointestinal disease or condition that would preclude adequate absorption of study treatment
- Presence of serious or unstable concomitant systemic disorder incompatible with the clinical study (eg, substance abuse; uncontrolled intercurrent illness including active infection; arterial thrombosis; unstable respiratory, hepatic, renal or cardiac disease; and other active malignancy)
- Pregnant or breastfeeding females and male or female patients who refuse to use adequate contraception during the study and for 16 weeks after the last dose of study treatment
- Any contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipients
Sites / Locations
- Washington University School of Medicine
- Levine Cancer Institute
- Tennessee Oncology, PLLC - The Sarah Cannon Research Institute
- Virginia Cancer Specialists
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Rociletinib and Trametinib
Arm Description
Outcomes
Primary Outcome Measures
Incidence of treatment-emergent adverse events
Treatment emergent adverse events (AEs), laboratory abnormalities and ECG abnormalities in EGFR-mutant NSCLC patients given oral rociletinib in combination with oral trametinib; defining in Phase 1 the recommended combination dose for further evaluation in Phase 2
Objective Response Rate (ORR)
ORR according to RECIST Version 1.1 as determined by Investigator assessment
Cmax of rociletinib and trametinib at steady state
Tmax of rociletinib and trametinib at steady state
AUC of rociletinib and trametinib at steady state
Cmin of rociletinib and trametinib at steady state
t1/2 of rociletinib at steady state
Secondary Outcome Measures
Duration of Response (DR) According to RECIST Version 1.1
DR according to RECIST Version 1.1 as determined by Investigator assessment
Disease Control Rate (DCR) According to RECIST Version 1.1
DCR according to RECIST Version 1.1 as determined by Investigator assessment
Progression Free Survival (PFS) According to RECIST Version 1.1
PFS according to RECIST Version 1.1 as determined by Investigator assessment
Overall Survival (OS)
Longitudinal changes in blood based biomarkers (i.e. mutations in EGFR) in ctDNA
Cmax of rociletinib metabolites at steady state
Tmax of rociletinib metabolites at steady state
AUC of rociletinib metabolites at steady state
Cmin of rociletinib metabolites at steady state
Full Information
NCT ID
NCT02580708
First Posted
October 12, 2015
Last Updated
September 28, 2018
Sponsor
Clovis Oncology, Inc.
Collaborators
Novartis Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT02580708
Brief Title
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
Official Title
A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Lung Cancer (NSCLC)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Terminated
Why Stopped
Discontinued development of rociletinib in NSCLC. Stopped enrollment of new patients into all studies involving rociletinib.
Study Start Date
September 30, 2015 (Actual)
Primary Completion Date
May 5, 2016 (Actual)
Study Completion Date
June 27, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clovis Oncology, Inc.
Collaborators
Novartis Pharmaceuticals
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
Detailed Description
This is a Phase 1/2, open-label, non randomized, multicenter study evaluating the safety and efficacy of rociletinib administered in combination with trametinib.
This study will be conducted in 2 phases:
Phase 1: This will be the dose escalation phase of the study. Phase 1 will determine the MAD or MTD and RP2D of the combination of rociletinib and trametinib, and evaluate its safety and tolerability and PK profile in EGFRm NSCLC patients who have failed at least one prior EGFR TKI.
Phase 2: This will be the dose expansion phase. Phase 2 will evaluate the preliminary efficacy and pharmacodynamics of the combination of rociletinib and trametinib at the RP2D in two subsets of EGFRm NSCLC patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
7 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Rociletinib and Trametinib
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Rociletinib
Other Intervention Name(s)
CO-1686
Intervention Type
Drug
Intervention Name(s)
Trametinib
Other Intervention Name(s)
Mekinist
Primary Outcome Measure Information:
Title
Incidence of treatment-emergent adverse events
Description
Treatment emergent adverse events (AEs), laboratory abnormalities and ECG abnormalities in EGFR-mutant NSCLC patients given oral rociletinib in combination with oral trametinib; defining in Phase 1 the recommended combination dose for further evaluation in Phase 2
Time Frame
Continuously, up to approximately 24 months
Title
Objective Response Rate (ORR)
Description
ORR according to RECIST Version 1.1 as determined by Investigator assessment
Time Frame
Every 6 weeks until disease progression, up to approximately 24 months
Title
Cmax of rociletinib and trametinib at steady state
Time Frame
Cycle 2 Day 1 to Day 2
Title
Tmax of rociletinib and trametinib at steady state
Time Frame
Cycle 2 Day 1 to Day 2
Title
AUC of rociletinib and trametinib at steady state
Time Frame
Cycle 2 Day 1 to Day 2
Title
Cmin of rociletinib and trametinib at steady state
Time Frame
Cycle 2 Day 1 to Day 2
Title
t1/2 of rociletinib at steady state
Time Frame
Cycle 2 Day 1 to Day 2
Secondary Outcome Measure Information:
Title
Duration of Response (DR) According to RECIST Version 1.1
Description
DR according to RECIST Version 1.1 as determined by Investigator assessment
Time Frame
Every 6 weeks until disease progression, up to approximately 24 months
Title
Disease Control Rate (DCR) According to RECIST Version 1.1
Description
DCR according to RECIST Version 1.1 as determined by Investigator assessment
Time Frame
Every 6 weeks until disease progression, up to approximately 24 months
Title
Progression Free Survival (PFS) According to RECIST Version 1.1
Description
PFS according to RECIST Version 1.1 as determined by Investigator assessment
Time Frame
Every 6 weeks until disease progression, up to approximately 24 months
Title
Overall Survival (OS)
Time Frame
Every 12 weeks until date of death, up to approximately 60 months
Title
Longitudinal changes in blood based biomarkers (i.e. mutations in EGFR) in ctDNA
Time Frame
Biomarker samples will be collected from each subject approximately every 3 weeks, up to approximately 24 months
Title
Cmax of rociletinib metabolites at steady state
Time Frame
Cycle 2 Day 1 to Day 2
Title
Tmax of rociletinib metabolites at steady state
Time Frame
Cycle 2 Day 1 to Day 2
Title
AUC of rociletinib metabolites at steady state
Time Frame
Cycle 2 Day 1 to Day 2
Title
Cmin of rociletinib metabolites at steady state
Time Frame
Cycle 2 Day 1 to Day 2
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent on an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved ICF before any study-specific evaluation
Histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with EGFR activating mutation (excluding exon 20 insertion); measurable disease per RECIST 1.1
Prior treatment with an EGFR TKI; in Phase 2, prior treatment with a T790M-directed EGFR TKI for patients in Group B. Previous chemotherapy is allowed; in Phase 2, immediate prior therapy must be EGFR TKI
Patient willingness to undergo tumor biopsy at baseline and on treatment (optional for Phase 1; mandatory for Phase 2)
Eastern Cooperative Oncology Group (ECOG) performance status 0-1; life expectancy at least 3 months
Adequate hematological and biological function; LVEF ≥50%
Exclusion Criteria:
Documented evidence in tumor of exon 20 insertion, small cell transformation, or MET amplification
Leptomeningeal carcinomatosis or other untreated or symptomatic CNS metastases (asymptomatic CNS metastases allowed if clinically stable without requirement for steroids within 2 weeks)
Known preexisting interstitial lung disease or pneumonitis
Concurrent use of QT-prolonging medication
Uncontrolled diabetes (HA1C > 10%) despite optional therapy
Cardiac abnormalities:
Clinically significant abnormal 12-lead ECG, QT interval corrected using Fridericia's method (QTcF) >450 ms
Inability to measure QT interval on ECG
Personal or family history of long QT syndrome
Implantable pacemaker or implantable cardioverter defibrillator
Resting bradycardia < 55 beats/min
Inability to swallow oral study treatment or any gastrointestinal disease or condition that would preclude adequate absorption of study treatment
Presence of serious or unstable concomitant systemic disorder incompatible with the clinical study (eg, substance abuse; uncontrolled intercurrent illness including active infection; arterial thrombosis; unstable respiratory, hepatic, renal or cardiac disease; and other active malignancy)
Pregnant or breastfeeding females and male or female patients who refuse to use adequate contraception during the study and for 16 weeks after the last dose of study treatment
Any contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paula O'Connor, MD
Organizational Affiliation
Clovis Oncology, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Levine Cancer Institute
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
Tennessee Oncology, PLLC - The Sarah Cannon Research Institute
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Virginia Cancer Specialists
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
We'll reach out to this number within 24 hrs